MA
HZNP

Montag & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Montag & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22
Closed -$2.5K – 968
2022
Q4 		$2.5K Buy
+22
New +$1.83K ﹤0.01% 863

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Montag & Associates's HZNP Position: Q1 2023 in Review

Montag & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 22 shares — an estimated $2.5K sold.

Montag & Associates first reported a position in HZNP in Q4 2022 and held it in 1 quarter. The position peaked at $2.5K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Montag & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Montag & Associates sold 22 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $2.5K.
  • Montag & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 1 quarter.
  • Montag & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.5K in Q4 2022.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Montag & Associates's 13F filing for Q1 2023, filed 11 May 2023.